Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Oncology Letters
Join Editorial Board Propose a Special Issue
Print ISSN: 1792-1074 Online ISSN: 1792-1082
Journal Cover
April 2013 Volume 5 Issue 4

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
April 2013 Volume 5 Issue 4

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Cytotoxic and apoptosis‑inducing properties of a C21‑steroidal glycoside isolated from the roots of Cynanchum auriculatum

  • Authors:
    • Liang‑Fei Ye
    • Yi‑Qi Wang
    • Bo Yang
    • Ru‑Song Zhang
  • View Affiliations / Copyright

    Affiliations: Department of Pharmacy, Zhejiang Chinese Medical University, Hangzhou 310053, P.R. China
  • Pages: 1407-1411
    |
    Published online on: February 7, 2013
       https://doi.org/10.3892/ol.2013.1186
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

The present study aimed to investigate the anticancer effect of a C21‑steroidal glycoside (CG) isolated from the roots of Cynanchum auriculatum. CG was able to inhibit the growth of human cancer cells (SGC‑7901 cells) in a concentration and time‑dependent manner in vitro. SGC‑7901 cells exposed to CG (10.8 and 21.6 µM) exhibited typical morphological apoptosis characteristics, such as nuclear‑chromatin condensation and apoptotic body formation. Flow cytometric analysis showed that after treatment with CG at 10.8 and 21.6 µM for 24 h, the percentage of apoptotic cells increased to 30.4 and 43.2%, respectively, while the number of cells in the G0/G1, S and G2/M phases of the cell cycle decreased (P<0.05). Furthermore, treatment with CG at a concentration of 21.6 µM for 24 h significantly increased the expression of caspase‑3 and the activity of caspase‑3 was increased ~3‑fold in SGC‑7901 cells. These results suggest that CG is the active anticancer component of the total C21‑glycosides of the roots of Cynanchum auriculatum which is able to inhibit the growth of cancer cells and induce cancer cell apoptosis through caspase‑3‑dependent pathways.

Introduction

The search for effective anticancer agents has been one of the most important areas in cancer control research. There are numerous natural plants used in clinical therapy for cancer in traditional Chinese medicine. The root of Cynanchum auriculatum Royle ex Wight, also known as Baishouwu, has been widely used in clinics since ancient times as an agent for anti-aging and prolonging life. Its major components, C21-steroidal glycosides (CG), are of considerable interest due to their bioactivities. Previous studies have revealed that the CGs isolated from Baishouwu were able to protect hepatocytes and neurons, as well as cells in the digestive system (1–3). Studies have also revealed the anticancer activity of these compounds (4–8). A number of CGs have been isolated from the roots of Cynanchum auriculatum Royle ex Wight. CG (Fig. 1) was one of the C21-steroidal glycosides obtained from Baishouwu and was first isolated by Warashina et al in 1995 (9). Few of the pharmacological functions of this compound have been reported. This compound attracted our attention due to its anticancer activity, which was more marked than that of the C21-steroidal glycosides previously reported (8). To further understand the potential anticancer properties of this compound, CG’s cytotoxic and apoptosis-inducing activities in several human cancer cells lines were studied.

Figure 1

Chemical structure of CG.

Materials and methods

Cell lines

The human gastric cancer (SGC-7901), human colon cancer (HT-29) and human hepatoma (HEPG-2) cell lines were obtained from the Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (Shanghai, China). The cells were incubated at 37°C in humidified air containing 5% CO2.

Concentration-dependent inhibitory effect assay

The SGC-7901, HT-29 and HEPG-2 cell viability was determined with an MTT assay. In brief, cells (3×103) were seeded in 96-well microtiter plates with each well containing culture medium (100 μl) supplemented with 10% FBS and incubated at 37°C overnight. The cells were then treated with CG (2.7, 5.4, 10.8, 21.6 and 43.2 μM) or DMSO (0.1%, negative control). Following incubation for 48 h, 20 μl of MTT solution (5 g/l) was added to each well. After 4 h of incubation at 37°C, the medium was discarded, DMSO (150 μl) was added to each well and the optical density (OD) was measured at 570 nm using an ELISA Elx8000 plate reader (BioTek, Winooski, VT, USA). The cell viability was measured using the OD values. The rate of inhibition was calculated by the following equation: Viability inhibition = (ODc − ODt) / ODc × 100, where ODc is the optical density of the control group and ODt is the optical density of the drug-treated group. Based on the viability inhibition rate, the IC50 (concentration required to inhibit the cell viability by 50%) values were then calculated with NDST software (BioGuider Medicinal Technology, China).

Time-dependent inhibitory effect assay

SGC-7901 cells were plated as described in the previous section. The cells were left to adhere overnight, then treated with CG (5.4–21.6 μM) or 0.1% DMSO for 0, 24, 48 and 72 h. At the end of each treatment, the cell viability was determined using an MTT assay as described previously.

Flow cytometry analysis

Propidium iodide (PI) staining was used to analyze cell apoptosis and the cell cycle. SGC-7901 cells (1×106) were seeded in culture flasks prior to drug treatment. The cells were left to adhere overnight, then treated with CG (10.8 and 21.6 μM) or DMSO (0.1%) for 24 h. At the end of the treatment, the cells were trypsinized and washed twice with ice-cold PBS, then fixed with ice-cold 70% ethanol in PBS at 4°C. The fixed cells were then centrifuged and washed with staining buffer. After washing, the pellets were treated with 100 μl RNase A (1 g/l) for 30 min at 37°C. After the incubation, 900 μl staining buffer and 20 μl PI (1 g/l) were added to each sample and incubated in the dark for 30 min. The samples were then analyzed with a FACSCalibur flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA).

Morphological analysis

SGC-7901 cells (1×105) were seeded in 6-well culture plates with each well containing medium (2 ml). The cells were left to adhere overnight, then treated with CG (10.8 and 21.6 μM) or 0.1% DMSO for 24 h. Following drug treatment, the medium was discarded and the cells were washed twice with PBS. The cells were then observed with a light microscope (Olympus, Tokyo, Japan) or stained with acridine orange (5 μl) for 10 min at room temperature in the dark and observed under a fluorescence microscope (Olympus).

Determination of cleaved caspase-3 production

Cells (5×106) in medium (20 ml) were transferred to each flask (75 cm2) prior to drug treatment. The cells were left to adhere overnight, then treated with CG (10.8 and 21.6 μM) or DMSO (0.1%) for 24 h. At the end of the treatment, the cells were harvested and washed twice with ice-cold PBS, then lysed with lysis buffer (100 μl). Proteins for the assay were obtained by collecting the supernatant and were used for the determination of cleaved caspase-3 by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and western blot analysis. The procedure was as follows: The protein concentration in the supernatant was determined using a BCA protein assay kit (KeyGen, Nanjing, China) with albumin as the standard. Equal amounts of proteins (60 μg) from each group were loaded onto SDS-PAGE gels (12.5%) and electrophoresed to separate the proteins. The proteins from the gels were transferred onto nitrocellulose membranes. The membranes were blocked with non-fat milk (5%) in TBS (10 mM Tris and 100 mM NaCl) for 1 h and probed with primary antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA) against cleaved caspase-3 and β-actin, followed by an appropriate horseradish peroxidase-conjugated secondary antibody (Zhongshan Bio-Tech Co., Ltd., Zhongshan, China) and ECL detection.

Colorimetric caspase-3 activity assays

Caspase-3 activity was measured using a colorimetric assay kit (KeyGen) according to the the manufacturer’s instructions. In brief, the cells were plated and treated as described for the determination of cleaved caspase-3 production. At the end of the treatment, the cells were harvested, washed twice with ice-cold PBS and lysed for 60 min on ice in the lysis buffer provided in the kit. The proteins were collected by centrifuging at 10,000 × g for 1 min. The protein concentration in the supernatant was determined using a BCA protein assay kit (KeyGen) and samples were diluted to a concentration of 2 g/l using lysis buffer. Samples containing 50 μg of proteins in lysis buffer (100 μl) were added to the reaction buffer and caspase-3 substrates to measure the caspase-3 activity. The samples were incubated at 37°C for 4 h. The absorbance density was measured using a spectrophotometer (Amersham, Piscataway, NJ, USA) at 400 nm.

Statistical analysis

The data are expressed as the mean ± SD. Values were analyzed with SPSS 16.0 software for Windows and the statistical significance of differences among the values was evaluated by one-way ANOVA. P<0.05 was considered to indicate a statistically significant difference.

Results

Concentration-dependent inhibitory effect of CG on three human cancer cell lines

The cytotoxicity of CG against three human cancer-cell lines; gastric cancer cell line (SGC-7901), colon cancer cell line (HT-29) and hepatoma cell line (HEPG-2), was determined. The cell viability was evaluated by measuring the mitochondrial metabolic activity of the cells using MTT assays. A concentration-dependent decrease in optical density at 570 nm (OD570nm) was observed following CG treatment in all three cell lines (Fig. 2). The cell viability inhibition rates were also calculated. Treatment with CG (2.7 43.2 μM) for 48 h resulted in 11.9 to 85.3% decrease in cell viability in HEPG 2 cells, 10 to 75.9% decrease in HT29 cells and 9 to 81.4% decrease in SGC 7901 cells. The IC50 values of CG in the HEPG 2, HT 29 and SGC 7901 cell lines are 12.2, 16.4 and 12.6 μM, respectively (Table I).

Figure 2

Concentration-dependent inhibitory effect of CG on three human cancer cell lines. The cells were treated with CG (0–43.2 μM) for 48 h and MTT assays were used to analyze the cell viability. The data are presented as the mean ± SD, n=3.

Table I

IC50 values of CG against three human cancer cell lines (mean ± SD, n=3).

Table I

IC50 values of CG against three human cancer cell lines (mean ± SD, n=3).

Cancer cell lineCell typeIC50 (μM)
HEPG-2Liver12.2±0.6
HT-29Colon16.4±2.1
SGC-7901Stomach12.6±0.5
Time-dependent inhibitory effect of CG on SGC-7901 cells

To further understand the time-dependent inhibitory effect of CG, SGC-7901 cells were treated with CG (5.4–21.6 μM) for 24, 48 and 72 h and an MTT assay was used to evaluate the cell viability. As shown in Fig. 3, the untreated SGC-7901 cells grew in an unrestrained manner and the OD570 nm increased noticeably with the culture time. However, in the SGC-7901 cells treated with CG, the OD570 nm increased slowly. At 21.6 μM, the OD570 nm did not increase with the culture time and the cell viability was inhibited by >50% compared with the control, even when the SGC-7901 cells were only treated for 24 h.

Figure 3

Time-dependent inhibitory effect of CG on SGC-7901 cells. The cells were treated with CG (0–21.6 μM) for 0, 24, 48 and 72 h and MTT assays were used to analyze the cell viability. The data are presented as the mean ± SD, n=3.

Cell cycle distribution and apoptosis rate in SGC-7901 cells

In order to gain an improved understanding of the cell growth inhibition mechanism, the effects of CG on the cell cycle distribution and apoptosis rate of SGC-7901 cells were investigated. PI, a fluorescent dye, was used to stain the nuclear chromatin and flow cytometry was used to analyze cell apoptosis and the cell cycle according to the content of the cell chromatin. The total analyzed cells were separated into four groups; apoptosis, G0/G1, S and G2/M with regard to the distribution of DNA content. The gray area in Fig. 4A denotes the number of the cells in each group. As shown in Fig. 4, after the cells were treated with CG at 10.8 and 21.6 μM for 24 h, the percentage of apoptotic cells increased to 30.4 and 43.2% respectively (P<0.001) while the cells in the G0/G1, S and G2/M phases decreased (P<0.05).

Figure 4

Effect of CG on apoptosis rate and cell cycle distribution in SGC-7901 cells. (A) Cell DNA content distribution in SGC-7901 cells with the treatment of various concentrations of CG. The cells were treated at drug concentrations of (a) 0, (b) 10.8 and (c) 21.6 μM for 24 h and then stained with PI and analyzed by flow cytometry. (B) Apoptosis rate summarized from the cell DNA content distribution. (C) The percentage of cells distributed in each cell cycle summarized from the cell DNA content distribution. The data are presented as the mean ± SD, n=3. *P<0.05, **P<0.01, ***P<0.001, compared with the control. PI, propidium iodide.

Morphological changes in SGC-7901 cells

To confirm the apoptosis-inducing properties of CG, the morphological changes in SGC-7901 cells were studied. Under the light microscope, it was observed that the untreated SGC-7901 cells grew in an unrestricted manner with tight contact between neighboring cells. After being treated with CG (10.8 μM) for 24 h, the gaps between the SGC-7901 cells became larger and a number of the cells shrank and became round in shape. When treated with CG at 21.6 μM, the cell morphology changed significantly and the majority of the cells became round in shape (Fig. 5A). To observe the nuclear morphological changes, acridine orange, a fluorescent dye which binds to nuclear chromatin, was used. Under the fluorescence microscope, it was observed that the fluorescent dye was distributed evenly in the nuclei of SGC-7901 cells in the control group (Fig. 5Ba). When the cells were exposed to CG (10.8 and 21.6 μM) for 24 h, clear apoptotic characteristics, such as chromatin condensation, nuclear fragmentation and apoptotic bodies, were observed in numerous cells. The morphological changes became more distinct when the concentration of CG was increased (Fig. 5Bb and c).

Figure 5

Morphological changes in SGC-7901 cells treated with CG. The cells were treated at drug concentrations of (a) 0, (b) 10.8 and (c) 21.6 μM for 24 h and then (A) observed under a light microscope or (B) stained with acridine orange and observed with a fluorescence microscope. Magnification, ×400.

Caspase-3 acivation in SGC-7901 cells

To further demonstrate the apoptosis-inducing effect of CG, the activation of protease caspase-3, which is activated in the classic apoptosis pathway and used as a marker of apoptosis induction (10), was studied. The results showed that CG (10.8 and 21.6 μM) treatment for 24 h increased the production of cleaved caspase-3 in a concentration-dependent manner. As shown in Fig. 6A, the western blot analysis results revealed two bands at 19 and 17 kDa, which were the bands for cleaved caspase-3. The cleaved caspase-3 bands of the control were extremely faint. CG (10.8 and 21.6 μM) treatment for 24 h increased the intensity of the two bands, particularly at 21.6 μM. To further confirm the activation of caspase-3, a colorimetric assay kit (KeyGen) was used to examine the activity of caspase-3. The enzymatic activity of caspase-3 was quantified by measuring chromophores obtained from the cleaved substrates. As shown in Fig. 6B, after treatment with CG (10.8 and 21.6 μM) for 24 h, the absorbance at 405 nm, denoting the caspase-3 activity, increased significantly (P<0.01). At 21.6 μM, the activity of caspase-3 was increased ∼3-fold.

Figure 6

Effect of CG on caspase-3 activation in SGC-7901 cells. Cells were treated with CG (0–21.6 μM) for 24 h and total cell lysates were prepared for (A) SDS-PAGE and western blot analysis or (B) enzymatic activity in the cell lysates was quantified by measuring chromophores obtained from the cleaved substrates. The data are presented as the mean ± SD, n=3. **P<0.01, ***P<0.001, compared with the control. #P<0.001 compared with the group treated with CG at 10.8 μM. SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis.

Discussion

In our previous study, we isolated four new C21-steroidal glycosides from the roots of Cynanchum auriculatum and reported the anticancer activity of auriculoside A (AA) which was the most active of the four (8,11,12). In the present study, CG, a C21-steroidal glycoside first isolated by Warashina et al in 1995, demonstrated greater cytotoxic effects than AA. The IC50 values of CG, which ranged between 12.2 and 16.4 μM, were lower than those of AA, which ranged between 23.2 and 36.7 μM (8). Furthermore, the IC50 values of CG were lower than the C21-steroidal glycosides reported by other studies. For example, the IC50 value of caudatin, a C21-steroidal aglycone from the roots of Cynanchum auriculatum was reported to be 84.51 μM at 48 h in HEPG-2 (13). The great difference in the inhibitory effects of these C21-steroidal glycosides in similar cancer cells suggests that there may be certain rules governing the association between the structure and activity of this type of compound.

Apoptosis induction is a key event that is the target of numerous chemopreventive agents (13,14). C21-steroidal glycosides also show a clear apoptosis-inducing effect (6,8,13). Accordingly, the apoptosis-inducing properties of CG were investigated in the present study. The results showed that CG induced cancer cell apoptosis at a lower concentration than a number of other C21-steroidal glycosides (6,8,13). As analyzed by flow cytometry, 21.6 μM CG treatment for only 24 h induces apoptosis in >40% cells and this is consistent with its strong cytotoxicity in cancer cells in vitro. Morphological changes are clear evidence of apoptosis. Apoptotic cells are characterized by distinct morphological features, including cell shrinkage and loss of contact with neighboring cells, chromatin condensation, nuclear fragmentation and apoptotic body formation. To demonstrate the apoptosis-inducing effect of CG, the cell outline and nucleus were observed under light and fluorescence microscopes. It was revealed that SGC-7901 cells treated with CG exhibited typical apoptotic morphological features. Usually in apoptosis, caspase-3 is activated and this is often used as a marker of apoptosis induction (15). Activated caspase-3 is cleaved into two segments (cleaved caspase-3) with molecular weights of 17 and 19 kDa. Cleaved caspase-3 is able to activate deoxyribonuclease, leading to DNA fragmentation and apoptotic cell death (16). In the present study, the production of cleaved caspase-3 and the activity of caspase-3 were also investigated to assess caspase-3 activation. The results showed that the production of the two segments of cleaved caspase-3 and the activity of caspase-3 increased following CG treatment for 24 h particularly at 21.6 μM. Thus the apoptosis-inducing effect of CG was further demonstrated.

In conclusion, the present study demonstrated the cytotoxic and apoptosis-inducing properties of CG and showed that CG is a potent anticancer C21-steroidal glycoside from the roots of Cynanchum auriculatum. This study also emphasized the importance of comparing the pharmacological properties between the various C21-steroidal glycosides. In future research, emphasis should be placed on identifying the rules governing the association between the structure and activity of this type of compound.

Acknowledgements

This study was supported by the Zhejiang Provincial Health Department of China (grant No. 2011KYB055).

References

1 

Lee MK, Yeo H, Kim J and Kim YC: Protection of rat hepatocytes exposed to CCl4 in-vitro by cynandione A, a biacetophenone from Cynanchum wilfordii. J Pharm Pharmacol. 52:341–345. 2000. View Article : Google Scholar : PubMed/NCBI

2 

Lee MK, Yeo H, Kim J, Markelonis GJ, Oh TH and Kim YC: Cynandione A from Cynanchum wilfordii protects cultured cortical neurons from toxicity induced by H2O2, L-glutamate, and kainate. Neurosci Res. 59:259–264. 2000.

3 

Shan L, Liu RH, Shen YH, et al: Gastroprotective effect of a traditional Chinese herbal drug ‘Baishouwu’ on experimental gastric lesions in rats. J Ethnopharmacol. 107:389–394. 2006.

4 

Shan L, Zhang WD, Zhang C, Liu RH, Su J and Zhou Y: Antitumor activity of crude extract and fractions from root tuber of Cynanchum auriculatum Royle ex Wight. Phytother Res. 19:259–261. 2005. View Article : Google Scholar : PubMed/NCBI

5 

Liu K, Chen F and Zhang H: Antitumor effects by Wilfoside C3N treatment in ECA109 cells. Anticancer Drugs. 21:625–631. 2010. View Article : Google Scholar : PubMed/NCBI

6 

Peng YR, Ding YF, Wei YJ, Shu B, Li YB and Liu XD: Caudatin-2, 6-dideoxy-3-O-methy-β-D-cymaropyranoside 1 induced apoptosis through caspase 3-dependent pathway in human hepatoma cell line SMMC7721. Phytother Res. 25:631–637. 2011.

7 

Li Y, Zhang J, Gu X, Peng Y, Huang W and Qian S: Two new cytotoxic pregnane glycosides from Cynanchum auriculatum. Planta Med. 74:551–554. 2008. View Article : Google Scholar : PubMed/NCBI

8 

Zhang R, Liu Y, Wang Y, Ye Y and Li X: Cytotoxic and apoptosis-inducing properties of auriculoside A in tumor cells. Chem Biodivers. 4:887–892. 2007. View Article : Google Scholar : PubMed/NCBI

9 

Warashina T and Noro T: Steroidal glycosides from roots of Cynanchum caudatum M. Chem Pharm Bull (Tokyo). 43:977–982. 1995. View Article : Google Scholar

10 

Zhang RS, Ye YP, Shen YM and Liang HL: Studies on the cytotoxic constituents of Cynanchum auriculatum Royle ex Wight. Yao Xue Xue Bao. 35:431–437. 2000.

11 

Zhang RS, Ye YP, Shen YM and Liang HL: Two new cytotoxic C-21 steroidal glucosides from the root of Cynanchum auriculatum. Tetrahedron. 56:3875–3879. 2000. View Article : Google Scholar

12 

Fei HR, Chen HL, Xiao T, Chen G and Wang FZ: Caudatin induces cell cycle arrest and caspase-dependent apoptosis in HepG2 cell. Mol Biol Rep. 39:131–138. 2012. View Article : Google Scholar : PubMed/NCBI

13 

Sun SY, Hail NJ and Lotan R: Apoptosis as a novel target for cancer chemoprevention. J Natl Cancer Inst. 96:662–672. 2004. View Article : Google Scholar : PubMed/NCBI

14 

Kasibhatla S and Tseng B: Why target apoptosis in cancer treatment. Mol Cancer Ther. 2:573–580. 2003.PubMed/NCBI

15 

Nicholson DW and Thornberry NA: Caspases: killer proteases. Trends Biochem Sci. 22:299–306. 1997. View Article : Google Scholar

16 

Ghobrial IM, Witzig TE and Adjei AA: Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin. 55:178–194. 2005. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Ye LF, Wang YQ, Yang B and Zhang RS: Cytotoxic and apoptosis‑inducing properties of a C21‑steroidal glycoside isolated from the roots of Cynanchum auriculatum. Oncol Lett 5: 1407-1411, 2013.
APA
Ye, L., Wang, Y., Yang, B., & Zhang, R. (2013). Cytotoxic and apoptosis‑inducing properties of a C21‑steroidal glycoside isolated from the roots of Cynanchum auriculatum. Oncology Letters, 5, 1407-1411. https://doi.org/10.3892/ol.2013.1186
MLA
Ye, L., Wang, Y., Yang, B., Zhang, R."Cytotoxic and apoptosis‑inducing properties of a C21‑steroidal glycoside isolated from the roots of Cynanchum auriculatum". Oncology Letters 5.4 (2013): 1407-1411.
Chicago
Ye, L., Wang, Y., Yang, B., Zhang, R."Cytotoxic and apoptosis‑inducing properties of a C21‑steroidal glycoside isolated from the roots of Cynanchum auriculatum". Oncology Letters 5, no. 4 (2013): 1407-1411. https://doi.org/10.3892/ol.2013.1186
Copy and paste a formatted citation
x
Spandidos Publications style
Ye LF, Wang YQ, Yang B and Zhang RS: Cytotoxic and apoptosis‑inducing properties of a C21‑steroidal glycoside isolated from the roots of Cynanchum auriculatum. Oncol Lett 5: 1407-1411, 2013.
APA
Ye, L., Wang, Y., Yang, B., & Zhang, R. (2013). Cytotoxic and apoptosis‑inducing properties of a C21‑steroidal glycoside isolated from the roots of Cynanchum auriculatum. Oncology Letters, 5, 1407-1411. https://doi.org/10.3892/ol.2013.1186
MLA
Ye, L., Wang, Y., Yang, B., Zhang, R."Cytotoxic and apoptosis‑inducing properties of a C21‑steroidal glycoside isolated from the roots of Cynanchum auriculatum". Oncology Letters 5.4 (2013): 1407-1411.
Chicago
Ye, L., Wang, Y., Yang, B., Zhang, R."Cytotoxic and apoptosis‑inducing properties of a C21‑steroidal glycoside isolated from the roots of Cynanchum auriculatum". Oncology Letters 5, no. 4 (2013): 1407-1411. https://doi.org/10.3892/ol.2013.1186
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team